This Horizon Europe Cancer Mission call funds large-scale, multinational, investigator-initiated pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers, with lung cancer explicitly named as a primary refractory cancer type and immunotherapy resistance as a flagship focus. Projects must incorporate real-world effectiveness and patient quality-of-life endpoints. The Cancer Mission has attracted particular interest in lung cancer immunotherapy from countries both within and outside Europe. This is a single-stage call with no two-step LOI process.
Eligibility Criteria:
- Research consortia must comprise institutions in EU Member States or Horizon Europe Associated Countries (includes UK, Norway, Israel, Switzerland, and others)
- At least one lead participant must be based in a Horizon Europe-associated country
- Inclusion of clinical, academic, NGO, or industry partners is encouraged
- No citizenship restrictions for researchers within eligible institutions
- Projects must align with at least one Cancer Mission call topic
Funding Details:
- Approximately €7–8 million per project for up to 3 projects
- Covers research personnel, technology, consumables, and collaboration costs
Deadline:
- September 15, 2026, 17:00 CET (single-stage submission; no LOI process)
Where to go for further information: